Document is current

Article History

Accepted: 1 February 2024

First Online: 6 March 2024

Declarations

:

: NL is a scientific advisor to Telix Pharmaceuticals and a principal investigator on the ProstACT trials using Lu-TLX591. No other authors (KH, JC, SS and HN) have relevant financial or non-financial interests to declare.

: No funds, grants or other support was received for this study.

: Low or negligible risk research approval by St Vincent’s Hospital Human Research Ethics Committee (HREC), ETH00247 in accordance with the National Statement on Ethical Conduct in Human Research, 2007 (NHMRC). Cross-institutional approval reviewed by the University of Notre Dame HREC, 2023-052F in accordance with the National Statement on Ethical Conduct in Human Research.

: Not applicable

: Not applicable

: The datasets generated during and/or analysed during the current study are available from the corresponding author upon reasonable request.

: All authors contributed to the study’s conception and design. Material preparation, data collection and analysis were performed by NL, KH, JC, SS, and HN. The first draft of the manuscript was written by HN and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

: Not applicable